

## Appendix: Tables

1.	Sales January to December 2021 and 2020 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2021 vs. YTD December 2020.....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2021 vs. YTD December 2020 .....	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2021 vs. YTD December 2020 .....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International .....	11
11.	Roche Group consolidated income statement for the twelve months ended 31 December 2021 .....	12
12.	Roche Group core results reconciliation – Full Year 2021 .....	13
13.	Divisional core results reconciliation – Full Year 2021 .....	14
14.	Roche Group consolidated balance sheet .....	15
15.	Roche Group consolidated statement of cash flows .....	16

**1. Sales January to December 2021 and 2020**

CHF millions	Twelve months ended 31 December		% change	
	2021	2020	At CER	In CHF
Pharmaceuticals Division	45,041	44,532	3	1
United States	22,505	23,647	-2	-5
Europe	8,876	8,198	7	8
Japan	4,506	3,765	26	20
International*	9,154	8,922	4	3
Diagnostics Division	17,760	13,791	29	29
Roche Group	62,801	58,323	9	8

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020

CHF millions	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020
Pharmaceuticals Division	10,215	-7	10,600	-9	11,071	4	11,708	5	11,662	14
United States	5,258	-13	5,292	-14	5,510	0	5,905	0	5,798	8
Europe	1,930	-8	2,175	-6	2,310	15	2,125	1	2,266	19
Japan	963	-5	852	-7	956	7	1,378	60	1,320	46
International*	2,064	11	2,281	0	2,295	4	2,300	2	2,278	9
Diagnostics Division	4,129	28	4,330	55	4,712	48	4,263	18	4,455	8
Roche Group	14,344	1	14,930	3	15,783	14	15,971	8	16,117	12

\*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2021 vs. YTD December 2020

Top-selling pharmaceuticals January - December 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	5,055	19	3,777	14	916	34	-	-	362	50
Perjeta	3,955	4	1,416	-1	1,112	-4	268	-4	1,159	24
Actemra/RoActemra	3,562	27	1,761	49	915	15	382	10	504	5
Tecentriq	3,315	24	1,688	11	713	22	518	66	396	53
Avastin	3,056	-37	922	-47	430	-66	674	-1	1,030	-15
Hemlibra	3,022	41	1,815	34	609	61	365	23	233	102
Herceptin	2,694	-28	636	-52	544	-19	82	-38	1,432	-9
MabThera/Rituxan	2,565	-38	1,552	-44	268	-30	42	-30	703	-24
Kadcyla	1,982	16	813	4	687	21	130	53	352	29
Xolair	1,942	5	1,942	5	-	-	-	-	-	-
Ronapreve	1,630	-	-	-	727	-	645	-	258	-
Alecensa	1,356	18	366	10	297	11	247	8	446	40
Lucentis	1,353	-4	1,353	-4	-	-	-	-	-	-
Activase/TNKase	1,312	2	1,255	2	-	-	-	-	57	5
Esbriet	1,039	-5	732	-4	269	0	-	-	38	-28

\* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2021 vs. YTD December 2020

New products January - December 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	269	-1	173	-4	61	-2	-	-	35	28
Perjeta	3,955	4	1,416	-1	1,112	-4	268	-4	1,159	24
Kadcyla	1,982	16	813	4	687	21	130	53	352	29
Gazyva/Gazyvaro	678	9	313	10	223	4	62	-4	80	36
Esbriet	1,039	-5	732	-4	269	0	-	-	38	-28
Cotellic	50	0	14	18	17	-19	-	-	19	10
Alecensa	1,356	18	366	10	297	11	247	8	446	40
Tecentriq	3,315	24	1,688	11	713	22	518	66	396	53
Ocrevus	5,055	19	3,777	14	916	34	-	-	362	50
Hemlibra	3,022	41	1,815	34	609	61	365	23	233	102
Xofluza	4	-91	1	-97	-	-	-	-	3	-54
Polivy	247	48	92	-9	85	33	57	-	13	438
Rozlytrek	49	109	32	75	8	**	6	92	3	395
Phesgo	340	**	151	**	163	-	-	-	26	**
Enspryng	107	**	23	280	3	**	80	**	1	**
Evrysdi	602	**	365	**	113	-	19	-	105	**
Gavreto***	9	-	9	-	-	-	-	-	-	-
Ronapreve	1,630	-	-	-	727	-	645	-	258	-
Susvimo	1	-	1	-	-	-	-	-	-	-

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

\*\*\* January - June 2021 sales booked by partner Blueprint Medicines

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2021 vs. YTD December 2020

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	5,055	19	3,777	14	916	34	-	-	362	50
Perjeta	3,955	4	1,416	-1	1,112	-4	268	-4	1,159	24
Actemra/RoActemra	3,562	27	1,761	49	915	15	382	10	504	5
Tecentriq	3,315	24	1,688	11	713	22	518	66	396	53
Avastin	3,056	-37	922	-47	430	-66	674	-1	1,030	-15
Hemlibra	3,022	41	1,815	34	609	61	365	23	233	102
Herceptin	2,694	-28	636	-52	544	-19	82	-38	1,432	-9
MabThera/Rituxan	2,565	-38	1,552	-44	268	-30	42	-30	703	-24
Kadcyla	1,982	16	813	4	687	21	130	53	352	29
Xolair	1,942	5	1,942	5	-	-	-	-	-	-
Ronapreve	1,630	-	-	-	727	-	645	-	258	-
Alecensa	1,356	18	366	10	297	11	247	8	446	40
Lucentis	1,353	-4	1,353	-4	-	-	-	-	-	-
Activase/TNKase	1,312	2	1,255	2	-	-	-	-	57	5
Esbriet	1,039	-5	732	-4	269	0	-	-	38	-28
Gazyva	678	9	313	10	223	4	62	-4	80	36
Evrysdi	602	**	365	**	113	-	19	-	105	**
CellCept	592	-2	45	-25	154	-3	70	-8	323	5
Pulmozyme	566	-10	363	-14	117	-13	1	-9	85	22
Mircera	435	-5	-	-	55	-7	120	-18	260	4

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020
Ocrevus	1,052	10	1,226	16	1,212	31	1,283	7	1,334	25
Perjeta	954	20	988	2	980	7	1,006	2	981	3
Actemra/RoActemra	724	29	779	22	863	12	1,048	57	872	21
Tecentriq	723	35	775	26	824	31	878	23	838	17
Avastin	969	-35	863	-40	782	-40	745	-37	666	-30
Hemlibra	615	45	661	33	732	58	779	37	850	38
Herceptin	653	-43	755	-35	641	-35	665	-26	633	-6
MabThera/Rituxan	780	-43	705	-46	674	-34	589	-42	597	-26
Kadcyla	450	26	478	17	481	21	501	11	522	16
Xolair	453	3	409	-6	478	3	529	8	526	14
Ronapreve	-	-	166	-	429	-	489	-	546	-
Alecensa	319	54	298	14	333	25	357	18	368	15
Lucentis	324	-22	337	-7	328	2	352	-10	336	2
Activase/TNKase	316	11	304	-17	294	3	323	3	391	22
Esbriet	264	-9	256	-8	270	1	263	-5	250	-7
Gazyva	160	6	155	-2	169	18	177	10	177	10
Evrysdi	47	-	80	-	163	-	153	*	206	347
CellCept	144	-1	154	-5	144	-3	155	3	139	-2
Pulmozyme	142	-17	139	-23	137	-13	138	-7	152	5
Mircera	101	-24	105	-13	109	-10	117	1	104	5

\* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020
Ocrevus	798	5	914	9	935	28	930	0	998	23
Perjeta	338	0	360	-2	343	-3	376	2	337	-2
Actemra/RoActemra	270	19	305	10	384	3	611	143	461	67
Tecentriq	400	27	395	13	416	19	461	10	416	2
Avastin	306	-47	287	-48	243	-46	215	-50	177	-45
Hemlibra	368	30	398	21	439	49	480	36	498	33
Herceptin	195	-59	191	-57	157	-55	153	-52	135	-34
MabThera/Rituxan	499	-49	426	-53	429	-37	342	-49	355	-32
Kadcyla	190	11	200	5	201	6	212	0	200	3
Xolair	453	3	409	-6	478	3	529	8	526	14
Ronapreve	-	-	-	-	-	-	-	-	-	-
Alecensa	86	-4	77	-2	90	13	96	9	103	18
Lucentis	324	-22	337	-7	328	2	352	-10	336	2
Activase/TNKase	302	11	291	-17	279	2	309	2	376	22
Esbriet	186	-12	173	-8	188	0	195	-2	176	-7
Gazyva	71	5	74	0	79	28	79	3	81	11
Evrysdi	46	-	79	-	87	-	102	*	97	112
CellCept	15	-6	11	-31	12	-18	12	-18	10	-31
Pulmozyme	94	-24	85	-28	88	-21	89	-10	101	6
Mircera	-	-	-	-	-	-	-	-	-	-

\* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020
Ocrevus	184	20	217	37	205	40	267	36	227	26
Perjeta	292	4	301	-3	277	2	269	-8	265	-8
Actemra/RoActemra	215	24	239	12	217	20	207	10	252	18
Tecentriq	139	18	168	14	171	20	181	16	193	41
Avastin	170	-61	138	-68	119	-69	89	-69	84	-49
Hemlibra	112	99	136	71	156	123	148	26	169	53
Herceptin	143	-31	146	-25	131	-25	130	-20	137	-3
MabThera/Rituxan	75	-36	69	-45	65	-21	69	-33	65	-13
Kadcyla	156	34	167	24	169	29	172	16	179	16
Xolair	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	166	-	317	-	85	-	159	-
Alecensa	71	22	74	11	74	19	73	7	76	9
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	68	2	69	-10	68	9	65	0	67	0
Gazyva	56	15	51	-11	55	19	61	10	56	2
Evrysdi	-	-	-	-	27	-	35	-	51	*
CellCept	38	-10	38	-22	39	17	38	-2	39	3
Pulmozyme	34	4	30	-20	30	-7	29	-10	28	-15
Mircera	13	-17	13	-23	14	-7	14	-3	14	10

\* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	75	0	64	-11	68	-2	68	0	68	-3
Actemra/RoActemra	99	1	84	-2	98	15	103	25	97	5
Tecentriq	105	75	120	82	137	86	130	75	131	34
Avastin	183	-7	161	-8	169	0	172	5	172	0
Hemlibra	86	15	79	11	87	21	94	29	105	30
Herceptin	31	-43	22	-43	21	-37	20	-37	19	-36
MabThera/Rituxan	16	-34	10	-37	10	-34	11	-30	11	-17
Kadcyla	27	41	27	54	33	57	34	59	36	42
Xolair	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	-	-	360	-	285	-
Alecensa	67	29	55	8	63	10	63	11	66	5
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Gazyva	18	-9	14	1	17	-17	16	10	15	-7
Evrysdi	-	-	-	-	-	-	3	-	16	-
CellCept	21	1	17	-9	18	-7	17	-7	18	-9
Pulmozyme	0	-15	0	-23	0	-9	0	-18	1	22
Mircera	40	-18	29	-18	31	-15	30	-18	30	-21

**10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\***

CHF millions	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020
Ocrevus	70	55	95	77	72	41	86	35	109	51
Perjeta	249	135	263	23	292	34	293	16	311	24
Actemra/RoActemra	140	114	151	134	164	27	127	-14	62	-55
Tecentriq	79	86	92	84	100	56	106	62	98	24
Avastin	310	8	277	-4	251	-20	269	-11	233	-24
Hemlibra	49	325	48	214	50	92	57	138	78	55
Herceptin	284	-29	396	-16	332	-22	362	-7	342	17
MabThera/Rituxan	190	-24	200	-23	170	-30	167	-25	166	-15
Kadcyla	77	50	84	28	78	35	83	16	107	38
Xolair	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	112	-	44	-	102	-
Alecensa	95	**	92	44	106	59	125	40	123	25
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	14	1	13	-10	15	6	14	17	15	7
Esbriet	10	-9	14	0	14	-7	3	-73	7	-36
Gazyva	15	-1	16	21	18	23	21	43	25	56
Evrysdi	1	-	1	-	49	-	13	-	42	**
CellCept	70	4	88	11	75	-8	88	13	72	3
Pulmozyme	14	-7	24	3	19	40	20	12	22	45
Mircera	48	-30	63	-8	64	-8	73	13	60	25

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

## 11. Roche Group consolidated income statement for the twelve months ended 31 December 2021

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
<b>Sales</b>	<b>45,041</b>	<b>17,760</b>	-	<b>62,801</b>
Royalties and other operating income	2,969	80	-	3,049
Cost of sales	(10,634)	(9,013)	-	(19,647)
Marketing and distribution	(6,874)	(3,046)	-	(9,920)
Research and development	(12,993)	(1,806)	-	(14,799)
General and administration	(1,979)	(656)	(694)	(3,329)
<b>Operating profit</b>	<b>15,530</b>	<b>3,319</b>	<b>(694)</b>	<b>18,155</b>
Financing costs				(418)
Other financial income (expense)				(339)
<b>Profit before taxes</b>				<b>17,398</b>
Income taxes				(2,463)
<b>Net income</b>				<b>14,935</b>
Attributable to				
- Roche shareholders				13,930
- Non-controlling interests				1,005
<b>Earnings per share and non-voting equity security</b>				
Basic (CHF)				16.38
Diluted (CHF)				16.20

## 12. Roche Group core results reconciliation – Full Year 2021

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
<b>Sales</b>	<b>62,801</b>	-	-	-	-	-	-	-	-	<b>62,801</b>
Royalties and other operating income	3,049	-	-	-	-	-	-	-	-	3,049
Cost of sales	(19,647)	192	1,205	101	11	-	-	-	-	(18,138)
Marketing and distribution	(9,920)	424	37	15	-	-	-	-	-	(9,444)
Research and development	(14,799)	242	314	535	-	-	-	-	-	(13,708)
General and administration	(3,329)	504	-	-	44	118	-	-	-	(2,663)
<b>Operating profit</b>	<b>18,155</b>	<b>1,362</b>	<b>1,556</b>	<b>651</b>	<b>55</b>	<b>118</b>	-	-	-	<b>21,897</b>
Financing costs	(418)	-	-	-	2	4	-	-	-	(412)
Other financial income (expense)	(339)	-	-	-	-	-	-	-	-	(339)
<b>Profit before taxes</b>	<b>17,398</b>	<b>1,362</b>	<b>1,556</b>	<b>651</b>	<b>57</b>	<b>122</b>	-	-	-	<b>21,146</b>
Income taxes	(2,463)	(267)	(205)	(111)	(10)	(15)	-	-	(4)	(3,075)
<b>Net income</b>	<b>14,935</b>	<b>1,095</b>	<b>1,351</b>	<b>540</b>	<b>47</b>	<b>107</b>	-	-	<b>(4)</b>	<b>18,071</b>
Attributable to										
- Roche shareholders	13,930	1,081	1,343	534	47	107	-	-	(4)	17,038
- Non-controlling interests	1,005	14	8	6	-	-	-	-	-	1,033
EPS - diluted (CHF)	16.20	1.26	1.56	0.62	0.05	0.12	-	-	-	19.81

### 13. Divisional core results reconciliation – Full Year 2021

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
<b>Pharmaceuticals</b>								
Sales	45,041	-	-	-	-	-	-	45,041
Royalties and other operating income	2,969	-	-	-	-	-	-	2,969
Cost of sales	(10,634)	1	1,083	101	-	-	-	(9,449)
Marketing and distribution	(6,874)	324	18	15	-	-	-	(6,517)
Research and development	(12,993)	209	297	535	-	-	-	(11,952)
General and administration	(1,979)	326	-	-	23	86	-	(1,544)
<b>Operating profit</b>	<b>15,530</b>	<b>860</b>	<b>1,398</b>	<b>651</b>	<b>23</b>	<b>86</b>	<b>-</b>	<b>18,548</b>
<b>Diagnostics</b>								
Sales	17,760	-	-	-	-	-	-	17,760
Royalties and other operating income	80	-	-	-	-	-	-	80
Cost of sales	(9,013)	191	122	-	11	-	-	(8,689)
Marketing and distribution	(3,046)	100	19	-	-	-	-	(2,927)
Research and development	(1,806)	33	17	-	-	-	-	(1,756)
General and administration	(656)	63	-	-	21	29	-	(543)
<b>Operating profit</b>	<b>3,319</b>	<b>387</b>	<b>158</b>	<b>-</b>	<b>32</b>	<b>29</b>	<b>-</b>	<b>3,925</b>
<b>Corporate</b>								
General and administration	(694)	115	-	-	-	3	-	(576)
<b>Operating profit</b>	<b>(694)</b>	<b>115</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3</b>	<b>-</b>	<b>(576)</b>

## 14. Roche Group consolidated balance sheet

in millions of CHF	31 December 2021	31 December 2020	31 December 2019*
<b>Non-current assets</b>			
Property, plant and equipment	23,163	22,158	22,173
Right-of-use assets	1,249	1,112	1,145
Goodwill	10,809	9,249	10,295
Intangible assets	12,117	12,017	10,751
Deferred tax assets	5,583	5,459	4,979
Defined benefit plan assets	1,498	967	945
Other non-current assets	2,271	2,234	1,549
<b>Total non-current assets</b>	<b>56,690</b>	<b>53,196</b>	<b>51,837</b>
<b>Current assets</b>			
Inventories	7,715	7,194	6,055
Accounts receivable	10,806	10,154	10,440
Current income tax assets	320	149	237
Other current assets	3,755	3,111	2,664
Marketable securities	6,181	6,607	5,783
Cash and cash equivalents	6,850	5,727	6,075
<b>Total current assets</b>	<b>35,627</b>	<b>32,942</b>	<b>31,254</b>
<b>Total assets</b>	<b>92,317</b>	<b>86,138</b>	<b>83,091</b>
<b>Non-current liabilities</b>			
Long-term debt	(16,076)	(10,220)	(12,668)
Net deferred tax liabilities	(628)	(353)	(298)
Defined benefit plan liabilities	(6,103)	(7,831)	(7,480)
Provisions	(1,442)	(1,453)	(1,515)
Other non-current liabilities	(1,307)	(1,107)	(1,144)
<b>Total non-current liabilities</b>	<b>(25,556)</b>	<b>(20,964)</b>	<b>(23,105)</b>
<b>Current liabilities</b>			
Short-term debt	(15,122)	(3,996)	(1,695)
Current income tax liabilities	(3,002)	(3,679)	(3,838)
Provisions	(2,526)	(1,836)	(2,885)
Accounts payable	(4,637)	(4,121)	(3,822)
Other current liabilities	(13,129)	(11,769)	(11,879)
<b>Total current liabilities</b>	<b>(38,416)</b>	<b>(25,401)</b>	<b>(24,119)</b>
<b>Total liabilities</b>	<b>(63,972)</b>	<b>(46,365)</b>	<b>(47,224)</b>
<b>Total net assets</b>	<b>28,345</b>	<b>39,773</b>	<b>35,867</b>
<b>Equity</b>			
Capital and reserves attributable to Roche shareholders	24,489	36,341	32,747
Equity attributable to non-controlling interests	3,856	3,432	3,120
<b>Total equity</b>	<b>28,345</b>	<b>39,773</b>	<b>35,867</b>

\* The balance sheet at 31 December 2019 has been restated following the finalisation of the valuation of the net assets acquired related to the Spark Therapeutics acquisition in 2019.

## 15. Roche Group consolidated statement of cash flows

in millions of CHF	FY 2021	FY 2020
<b>Cash flows from operating activities</b>		
Cash generated from operations	26,600	25,614
(Increase) decrease in net working capital	(994)	(2,060)
Payments made for defined benefit plans	(619)	(601)
Utilisation of provisions	(1,166)	(1,390)
Disposal of products	496	239
Other operating cash flows	2	-
<b>Cash flows from operating activities, before income taxes paid</b>	<b>24,319</b>	<b>21,802</b>
Income taxes paid	(3,343)	(3,236)
<b>Total cash flows from operating activities</b>	<b>20,976</b>	<b>18,566</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(3,693)	(3,528)
Purchase of intangible assets	(856)	(3,162)
Disposal of property, plant and equipment	61	70
Disposal of intangible assets	-	-
Business combinations	(2,361)	(1,179)
Divestment of subsidiaries	7	3
Interest and dividends received	(2)	16
Sales of marketable securities	235	353
Purchases of marketable securities	(201)	(169)
Sales (purchases) of money market instruments and time accounts over three months, net	329	(1,181)
Other investing cash flows	(71)	(290)
<b>Total cash flows from investing activities</b>	<b>(6,552)</b>	<b>(9,067)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issue of bonds and notes	6,900	-
Redemption and repurchase of bonds and notes	(2,448)	-
Increase (decrease) in commercial paper	(1,134)	318
Increase (decrease) in other debt	13,412	341
Hedging and collateral arrangements	(522)	557
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(405)	(422)
Principal portion of lease liabilities paid	(382)	(369)
Dividends paid	(8,132)	(7,964)
Equity-settled equity compensation plans, net of transactions in own equity	(20,397)	(2,126)
Other financing cash flows	-	(1)
<b>Total cash flows from financing activities</b>	<b>(13,108)</b>	<b>(9,666)</b>
Net effect of currency translation on cash and cash equivalents	(193)	(181)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>1,123</b>	<b>(348)</b>
Cash and cash equivalents at beginning of period	5,727	6,075
<b>Cash and cash equivalents at end of period</b>	<b>6,850</b>	<b>5,727</b>